All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Daily Aspirin and Cancer Mortality

September 4th 2012

Recent analysis finds that mortality is reduced, but the association is smaller than previously reported.

Enzalutamide Approved for Late-Stage Prostate Cancer

August 31st 2012

The FDA approved enzalutamide for use in patients with metastatic castration-resistant prostate cancer who have been previously treated with docetaxel and hormonal therapy.

FDA Grants Priority Review to New Indication for Abiraterone Acetate

August 29th 2012

The FDA announced that Priority Review has been granted to abiraterone acetate for certain advanced prostate cancer cases based on positive data presented at the ASCO annual meeting.

FDA Approval Sought for T-DM1

August 27th 2012

Genentech is seeking the FDA's approval to offer T-DM1 for patients with HER2-positive metastatic breast cancer amid updated results from the pivotal EMILIA trial showing significantly improved OS.

Researchers Determine Immune Parameters that Lead to Better Survival in Patients who Receive Sipuleucel-T

August 17th 2012

Researchers have determined that patients who received sipuleucel-T (Provenge, Dendreon) developed immune parameters that correlate to improved overall survival, giving researchers a better understanding of how the immunotherapy works at a cellular level to improve survival.

Newly Published Results Show Survival Benefit with Enzalutamide in Prostate Cancer

August 16th 2012

The novel drug enzalutamide (formerly MDV3100) significantly improved overall survival in men with metastatic castrate-resistant prostate cancer (mCRPC).

Myriad Genetics Maintains BRCA1 and BRCA2 Patents, Appellate Court Rules

August 16th 2012

On August 16, the US Federal Circuit Court of Appeals ruled 2-1 to uphold its original decision that Myriad Genetics has the right to hold the patent to the BRCA1 and BRCA2 genes.

Hospital-Acquired Infection

August 14th 2012

More patients assigned per nurse and higher nurse burnout rates contribute to higher infection rates.

FDA Approves Marqibo for Rare Form of Leukemia

August 9th 2012

The FDA approved Marqibo to treat patients with Philadelphia chromosome-negative adult acute lymphoblastic leukemia following at least two relapses or failed treatment.

NDAs Filed for Two Melanoma Drugs

August 7th 2012

GlaxoSmithKline is seeking the FDA's approval for single-agent use of dabrafenib and trametinib, two targeted therapies for the treatment of patients with metastatic melanoma who harbor BRAF V600 gene mutations.

Combination of Anastrozole and Fulvestrant Improves Survival in Metastatic Breast Cancer

August 7th 2012

Researchers found that when anastrozole and fulvestrant are given in combination that patients with metastatic breast cancer experienced longer periods of PFS and OS.

Hepatitis C Infection

August 6th 2012

Transmission via healthcare workers is still occurring.

FDA Approves Aflibercept for Metastastic Colorectal Cancer

August 3rd 2012

The FDA announced that aflibercept has been approved to treat metastatic colorectal cancer when given in combination with the FOLFIRI chemotherapy regimen.

Patient Engagement

July 31st 2012

Principles for patient-centered care recently were released by the NAQC.

Geriatric Emergency Departments

July 25th 2012

Coming soon to a hospital near you?

FDA Approves Carfilzomib for Relapsed Multiple Myeloma

July 23rd 2012

The FDA approved carfilzomib for patients with multiple myeloma who have received at least two prior lines of therapy.

FDA Approves Everolimus for Advanced Breast Cancer

July 23rd 2012

The FDA has approved everolimus for treating patients with hormone receptor-positive, HER2 negative breast cancer, when given in combination with the aromatase inhibitor exemestane.

The Nurse Practitioner Workforce

July 17th 2012

We know more NPs are needed, but how many will be needed to meet future healthcare needs?

FDA Approves Cetuximab Plus FOLFIRI for Metastatic Colorectal Cancer

July 10th 2012

The FDA has approved cetuximab in combination with the FOLFIRI regimen as a first-line treatment for patients with mCRC who express EGFR and wild-type KRAS mutations.

The Reality of End-of-Life Care

July 9th 2012

Much remains to be done in the USA to improve the care of patients at end-of-life.